MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-06-11
Last Posted Date
2024-10-08
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT06453356
Locations
🇺🇸

Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield, Missouri, United States

🇺🇸

Bio-Kinetic Clinicals Applications LLC DBA QPS-MO Patient Screening and Recruitment Center Center), Springfield, Missouri, United States

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Phase 1
Terminated
Conditions
Advanced or Metastatic Solid Tumors
Colorectal Cancer
Non-Small Cell Lung Cancer
Urothelial Cancer
Melanoma
Interventions
First Posted Date
2024-06-07
Last Posted Date
2024-11-06
Lead Sponsor
Pfizer
Target Recruit Count
4
Registration Number
NCT06448364
Locations
🇵🇷

Hospital Oncológico Dr. Isaac González-Martinez, Rio Piedras, Puerto Rico

🇺🇸

NEXT Oncology, San Antonio, Texas, United States

🇵🇷

Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico

and more 3 locations

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Carcinoma, Pancreatic Ductal
Colorectal Neoplasms
Interventions
Combination Product: Gemcitabine
Combination Product: Cetuximab
Combination Product: Fluorouracil
Combination Product: Pembrolizumab
Combination Product: Nab-paclitaxel
Combination Product: Oxaliplatin
Combination Product: pemetrexed
Combination Product: Leucovorin
Combination Product: Cisplatin
Combination Product: Bevacizumab
Combination Product: Paclitaxel
Combination Product: Carboplatin
First Posted Date
2024-06-07
Last Posted Date
2025-05-13
Lead Sponsor
Pfizer
Target Recruit Count
330
Registration Number
NCT06447662
Locations
🇺🇸

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States

🇺🇸

Highlands Oncology Group, PA, Rogers, Arkansas, United States

🇺🇸

City of Hope Investigational Drug Service (IDS), Duarte, California, United States

and more 20 locations

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Phase 2
Completed
Conditions
Influenza, Human
Interventions
Biological: Influenza ModRNA Vaccine
Biological: Quadrivalent Influenza Vaccine (QIV)
First Posted Date
2024-05-31
Last Posted Date
2025-02-14
Lead Sponsor
Pfizer
Target Recruit Count
1202
Registration Number
NCT06436703
Locations
🇺🇸

Clinical Research Professionals, Chesterfield, Missouri, United States

🇺🇸

Artemis Institute for Clinical Research, San Diego, California, United States

🇺🇸

Duke Vaccine and Trials Unit, Durham, North Carolina, United States

and more 26 locations

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: tumor necrosis factor inhibitors (TNFi)
First Posted Date
2024-05-17
Last Posted Date
2025-01-22
Lead Sponsor
Pfizer
Target Recruit Count
21340
Registration Number
NCT06418529
Locations
🇺🇸

Pfizer, New York, New York, United States

A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Placebo
First Posted Date
2024-05-14
Last Posted Date
2024-11-20
Lead Sponsor
Pfizer
Target Recruit Count
31
Registration Number
NCT06413693
Locations
🇺🇸

Research Centers of America ( Hollywood ), Hollywood, Florida, United States

🇺🇸

Research Centers of America, Hollywood, Florida, United States

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

Completed
Conditions
Migraine Disorders
First Posted Date
2024-05-14
Last Posted Date
2025-01-13
Lead Sponsor
Pfizer
Target Recruit Count
528
Registration Number
NCT06412965
Locations
🇺🇸

Pfizer, New York, New York, United States

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting
Conditions
Colitis, Ulcerative
Interventions
First Posted Date
2024-05-03
Last Posted Date
2024-11-20
Lead Sponsor
Pfizer
Target Recruit Count
300
Registration Number
NCT06398626
Locations
🇺🇸

BI Research Center, Houston, Texas, United States

🇺🇸

Reddy GI Associates, Mesa, Arizona, United States

🇺🇸

Amicis Research Center, Valencia, California, United States

and more 10 locations

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Biological Availability
Healthy Participants
Interventions
First Posted Date
2024-05-02
Last Posted Date
2024-05-02
Lead Sponsor
Pfizer
Target Recruit Count
28
Registration Number
NCT06397144

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: PF-06954522 IR (Formulation 1)
Drug: PF-06954522 MR (Formulation 2)
Drug: PF-06954522 MR (Formulation 3)
First Posted Date
2024-05-01
Last Posted Date
2024-10-08
Lead Sponsor
Pfizer
Target Recruit Count
23
Registration Number
NCT06393517
Locations
🇺🇸

Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

🇺🇸

Pfizer Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath